Analyse
Fundierte Analysen zu Pharmamärkten, Lieferketten, Technologie und Regulierung
Analyse
7. Sept. 2026•1 Min. Lesezeit
KPA and Paju City Sign MOU to Build Joint Pharma Logistics Hub in Peace Economic Zone
The Korean Pharmaceutical Distribution Association and Paju city have signed an MOU to develop a 100,000‑pyeong pharmaceutical and biotech logistics complex within the Paju Peace Economic Zone.
Analyse
7. Sept. 2026•1 Min. Lesezeit
SK BioPharm Secures Global Rights to Biohaven’s Opakalim (BHV‑7000) for Epilepsy
SK BioPharm obtained exclusive global rights to Biohaven’s next‑generation epilepsy candidate Opakalim (BHV‑7000), prompting positive analyst commentary on its strategic impact.
Analyse
7. Sept. 2026•1 Min. Lesezeit
Celltrion's Ramcima SC and US Zimpenra post 4.56 trillion KRW H1 sales
Ramcima SC and Zimpenra together generated 4.562 trillion KRW in the first half of the year, with strong growth in Europe and the US.
Analyse
7. Sept. 2026•1 Min. Lesezeit
Hecto Healthcare to Showcase Probiotic and Baby/Kids Brands at Vitafoods Asia 2026 in Bangkok
Hecto Healthcare will exhibit its probiotic brand ‘DeeSiMoNe’ and baby‑kids line ‘Kim Seokjin LAB’ at Vitafoods Asia 2026 in Bangkok, aiming to boost global market presence.
1
Analyse
7. Sept. 2026•1 Min. Lesezeit
Pharmacy goodwill prices in Seoul area exceed typical sales‑multiple calculations
Two recent pharmacy transactions in the Seoul metropolitan area show goodwill values of 750 million KRW and 600 million KRW, diverging from the usual 25‑30× monthly prescription sales rule.
Analyse
6. Sept. 2026•1 Min. Lesezeit
EU establishes new supply chain for Visudyne to address shortage
EU sets up a new supply chain for Visudyne (verteporfin), highlighting coordinated effort to mitigate a long‑standing drug shortage.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Daewon Pharmaceutical Continues Production and Sale of Cough Expectorant KoDaewon
Daewon Pharmaceutical will keep producing and supplying the cough expectorant Ko Daewon Jeong, aiming to maintain patient convenience and avoid prescribing confusion.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Wells Fargo analysis: GLP-1 obesity drugs disrupt US healthcare revenue model
Wells Fargo reports that the rapid spread of GLP‑1 obesity treatments is shaking the profit structure of the US healthcare system, prompting providers, insurers and investors to rethink revenue sources.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Metropolitan pharmacy franchise fees diverge from traditional sales‑multiple formula
A 20‑pyeong pharmacy with 21 MKR monthly sales was priced at 750 MKR, while one with 30 MKR sales fetched 600 MKR, showing a shift from the usual 25‑30× sales rule.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Metagenics launches Korean market with free Phyto Multi multivitamin promotion
Metagenics, via Korean distributor Taejeon Group, offers a free Phyto Multi Multivitamin bottle with purchase of two SPM Active or One a Day products until the 31st.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Celltrion expands Omliclo omalizumab biosimilar line with 300 mg launch in Europe
Celltrion has introduced the 300 mg dose of its omalizumab biosimilar Omliclo in Germany, the UK and France, extending its European portfolio for chronic urticaria and allergic asthma.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Seltrion Tops K-Brand Index Pharma/Bio Sector in Korea
Seltrion was ranked the top pharma and biotech brand in Korea by the Asia Brand Research Institute’s K‑Brand Index, based on analysis of over 15 million online data points.